You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 387 ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)

Article metrics

Article menu

Download PDFPDF

Trials in progress abstract
387 ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)
Free

 

Online download statistics by month:

Online download statistics by month: December 2020 to October 2024

AbstractFullPdf
Dec 202091021
Jan 202141011
Feb 20214004
Mar 20215205
Apr 202170016
May 20211406
Jun 20214017
Jul 20212019
Aug 2021005
Sep 2021307
Oct 202160026
Nov 202143018
Dec 20216207
Jan 202263026
Feb 202293010
Mar 20221804
Apr 20222102
May 202271012
Jun 20225907
Jul 202285017
Aug 202210809
Sep 202288018
Oct 202272014
Nov 202292011
Dec 2022135016
Jan 20237909
Feb 2023125016
Mar 2023229027
Apr 2023141021
May 202311109
Jun 2023157023
Jul 2023118012
Aug 2023141018
Sep 2023101014
Oct 202397015
Nov 2023114019
Dec 202311307
Jan 20242401
Feb 20242801
Mar 202495027
Apr 202486011
May 20244307
Jun 20244407
Jul 20246205
Aug 202467018
Sep 20246406
Oct 20241001
Total34360582